Ramón Alemany

Institut d'Investigació Biomédica de Bellvitge — Spain

Biochemistry, Genetics and Molecular Biology · Life Sciences

57h-index10.7kcitations316works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(258), CAR-T cell therapy research(135), Cancer Research and Treatments(134), Viral Infectious Diseases and Gene Expression in Insects(81), RNA Interference and Gene Delivery(66)

Publications316 total

Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial
ESMO Open·2025Open Access
Toxicity and Biodistribution of the Oncolytic Virus VCN-01 Following Intracranial Injection in Syrian Hamsters
Human Gene Therapy·2025
4P T cell phenotype and repertoire are modulated by neoadjuvant chemotherapy (NACT) in high-grade serous ovarian cancer (HGSOC)
ESMO Open·2025· 1 citedOpen Access
Author response: Unraveling the power of NAP-CNB’s machine learning-enhanced tumor neoantigen prediction
2025Open Access
Unraveling the power of NAP-CNB’s machine learning-enhanced tumor neoantigen prediction
eLife·2025Open Access
Supplementary Figure S5 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025Open Access
Supplementary Figure S5 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025Open Access
Supplementary Figure S3 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025Open Access
Supplementary Table S1 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025Open Access
Supplementary Table S4 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025Open Access
Supplementary Figure S4 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025Open Access
Supplementary Table S4 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025Open Access
Supplementary Figure S2 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025Open Access
Supplementary Table S2 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025Open Access
Supplementary Table S2 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025Open Access
Supplementary Figure S3 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025Open Access
Supplementary Figure S1 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025Open Access
Supplementary Figure S2 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025Open Access
Supplementary Figure S1 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025Open Access
Supplementary Figure S4 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025Open Access
page 1 of 16Next →

Frequent Co-authors

Manel Cascalló(13), David T. Curiel(11), Juàn Fueyo(10), Rafael Moreno(8), Candelaria Gomez‐Manzano(7), Sònia Guedan(5), Juan J. Rojas(5), Gabriel Capellá(4), Cristina Balagué(4), Hong Jiang(4), W.K. Alfred Yung(4), Carlos Alberto Fajardo(4), Javier Garcı́a-Castro(4), Jordi Martínez‐Quintanilla(4), Miriam Bazán‐Peregrino(4), Athanassios P. Kyritsis(3), Kaori Suzuki(3), Dirk M. Nettelbeck(3), Akseli Hemminki(3), Martí Farrera-Sal(3)